Neuronal Nicotinic Receptors - October 2008
Subscribe now and your organization will receive the next 12 monthly issues of UpdatesPlus
Neuronal nicotinic receptor ligands are fast proceeding through clinical development as exciting candidates for multiple CNS disorders including Alzheimer's disease; Schizophrenia; ADHD; Depression; Pain and Addiction.
Are you involved in these areas; are you developing a nicotinic receptor ligand? If so UpdatesPlus is for you. This service, brought to you from the pharmaceutical analysts, LeadDiscovery, not only identifies all key breaking research, drug development news and clinical trials in this area, it also analyzes it.
Published monthly along with a fully up to date pipeline of nicotinic receptor therapeutics, UpdatesPlus offers a key insight into the strategy and development within the nicotinics arena. Offering an ideal intelligence tool for everyone from brand managers to medical directors and preclinical managers, UpdatesPlus is a must for all involved in this exciting new field of medicine
See December 2007 edition now (free sample copy)
Table of Contents
What's in the October 2008 edition of UpdatesPlus-Nicotinic Receptors?
- Your guide to Neuroscience, 2008: Are you going to Neuroscience 2008? We have produced an itinerary of key nicotinic presentations including backgrounders for those that we feel to be of especial interest
- An update on Memory Pharmaceuticals' phase 1 program for MEM 63908
- An update on En Vivo's EVP-6124: En Vivo has been developing EVP-6124. The company is now expanding the potential indications for this candidate
- Nicotinic research at Novartis: Novartis has published a key paper describing the pharmacology of JN403. This α7 receptor readily penetrates the CNS and has demonstrated efficacy in a panel of CNS disorder, not only those classically associated with α7 receptor agonists such as cognition but also anxiety, epilepsy and pain. We review this paper
- What is happening at Sanofi-Aventis: Sanofi-Aventis were developing the α7 partial agonist SSR180711. This diazabicyclononane entered phase 1 trials in 2007 however development has currently been suspended. Sanofi-aventis has now claimed a new series of azabicycloalkane derivatives
- Chantix/Champix sales and activity within the smoking cesation arena: We review the latest Champix/Chantix sales and activity around this controversial therapeutic. We highlight new reports of serious injury relating to Chantix as well as Pfizer's ongoing strategy to counter its negative press. We also discuss the new ban on smoking in India. LeadDiscovery was also at the ERS last month where Pfizer and the ERS had booths centering on smoking cesation - we analyze the presence of both.
- An update on Neurosearch's nicotinics activity: Neurosearch has provided an update of its nicotinics program. We evaluate new potential indications and give our view on the slow development of this candidate
- Accelerating development at Amgen? Amgen continues its efforts to develop an α4ß2 therapeutic. Recent activity has identified a potent candidate with improved pharmacokinetic properties.
- New patents published by Targacept and Abbott: Targacept has claimed a new series of diazabicycloalkanes. Abbott has published a series of patents claiming new azaadamantane derivatives. Each of these patents are described.
- Do nicotinic receptor ligands have the potential to revolutionize Parkinson's disease? The Parkinson’s Institute has claimed the use of nicotine for the treatment of levodopa-induced dyskinesia. The potential of nicotinic receptor ligands as treatments of Parkinson’s disease itself has been recognized for a number of years, however use as an adjunct to levodopa represents a new advance.
- Full and up to date pipeline
UpdatesPlus continuously tracks development activity behind all known nicotinic agonists, antagonists and modulators including: MEM 63908/R4996, ABT-107, TC-5619, EVP-6124, AZD-0328, SSR-180711, GTS-21,MEM 3454 (R3487), Varenicline (Chantix/Champix), TC-6499, ABT-560, AZD3480 (TC-1734), TC-5214, Ispronicline, ABT-894, ABT-089
Pricing & Delivery: UpdatesPlus is available on a subscription basis. A one-off payment will get you the next twelve monthly editions of UpdatesPlus-Nicotinic Receptors plus access to all past editions. UpdatesPlus is available for unlimited use within your company. Delivered in a powerpoint format, UpdatesPlus is both easy to use and also ready for use within a presentation setting
2008 issues:
About UpdatesPlus: Through DailyUpdates, LeadDiscovery has access to one of the most comprehensive sources of information for the drug development sector. UpdatesPlus takes this information and uses our industrial experience to provide a monthly analysis of breaking activity in selected indications and molecular targets. If this is the first time that you have heard of UpdatesPlus please take a moment to have a look at an example. If you would find such a service of use in your area contact us now.
Other users found this report page using the following search terms: Neuronal Nicotinic Receptors MEM 63908 R4996 ABT-107 TC-5619 EVP-6124 AZD-0328 SSR-180711 gts-21 MEM 3454 R3487 chantix champix Varenicline TC-6499 abt-560 AZD3480 TC-1734 tc-5214 ispronicline abt-894 ABT-089 nicotinic receptors cognition cognitive cias alzheimer amyloid depression smoking cessation alpha7 alpha6 alpha4beta2 nicotinic adhd alzheimers nicotine memory nicotinic receptors neuronal receptor varenicline champix chantix wellbutrin azd0328 nicotinic receptors nicotine receptor evp6124 review ssr180711 abt560 neuronal depression
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.